BIOKIN PHARMACEUTICAL(SH:688506) Xin Lang Cai Jing·2025-11-17 00:34Group 1 - The A-share pharmaceutical index has increased by 3.3% this week and 22.1% year-to-date, outperforming the CSI 300 by 4.4% and 4.5% respectively [1] - The Hang Seng Biotechnology Index has risen by 7.0% this week and 88.8% year-to-date, outperforming the Hang Seng Technology Index by 7.4% and 58.7% respectively [1] - Notable weekly gains in the pharmaceutical sector include: pharmaceutical commerce (+5.7%), chemical pharmaceuticals (+4.5%), traditional Chinese medicine (+4.1%), biological products (+2.7%), medical services (+1.8%), and medical devices (+1.8%) [1] Group 2 - Bai Li Tian Heng focuses on major tumor treatment needs and has developed a global pipeline of innovative candidate drugs, including three platforms: HIRE-ADC, GNC, and HIRE-ARC [2] - As of November 2025, the company has 17 clinical-stage candidate drugs, with 6 undergoing clinical trials in the United States [2] - The pipeline includes izabren (EGFR×HER3 ADC) as a core representative, with 3 global pivotal phase III trials and 10 pivotal phase III trials in China initiated [2] Group 3 - Kolun Pharmaceutical's generic version of Enzalutamide has been approved for market launch, marking it as the first approved generic in China [3] - Jin Fang Pharmaceutical has initiated the first phase III clinical trial for GFH375 (VS-7375), which is the second KRAS G12D inhibitor to enter phase III globally [4] Group 4 - Recommended sub-industry rankings include: innovative drugs > research services > CXO > traditional Chinese medicine > medical devices > pharmacies [4] - Specific companies to focus on from the innovative drug perspective include Bai Li Tian Heng, BeiGene, Kolun Botai Biological, Heng Rui Pharmaceutical, and Zai Lab [4] - From the PD1/VEGF dual antibody perspective, recommended companies include Sanofi, Kintor Pharmaceutical, and Rongchang Biopharmaceutical [4]